A retrospective study of of Andexanet Alfa Vs. Four-Factor Prothrombin Complex Concentrates in the Reversal of Life-Threatening Intracranial Hemorrhage
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Andexanet alfa (Primary) ; Prothrombin complex concentrate (Primary)
- Indications Intracranial haemorrhages
- Focus Adverse reactions
Most Recent Events
- 18 Jan 2023 New trial record
- 13 Dec 2022 Primary endpoint (30-day mortality) has not been met according to Results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition